News | February 17, 2022
Asahi Kasei to build new filter assembly plant in Japan
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
_256_384.jpg){kind=logo}
Shilpa Biologicals has tie-ups with Zydus to supply ZyCoV-D vaccine drug substance and Dr Reddy’s to make Sputnik V from its facility in Dharwad
Pegfilgrastim is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients receiving chemotherapy
Spikevax has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union, the UK, Israel
Go-ahead for pivotal clinical trial which is expected to commence by March
Biocon has reported consolidated financial results for the period ended December 31, 2021
The extended collaboration will provide services relating to small molecules for both Forbion and BGV portfolio companies active in the biopharmaceutical space
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
This surpasses the number of approvals supported in 2020
Subscribe To Our Newsletter & Stay Updated
